جستجوی مقالات مرتبط با کلیدواژه "cancer therapy" در نشریات گروه "پزشکی"

Gliomas are the most common lethal tumors of the brain associated with a poor prognosis and increased resistance to chemo-radiotherapy. Circular RNAs (circRNAs), newly identified noncoding RNAs, have appeared as critical regulators of therapeutic resistance among multiple cancers and gliomas. Since circRNAs are aberrantly expressed in glioma and may act as promoters or inhibitors of therapeutic resistance, we categorized alterations of these specific RNAs expression in therapy resistant-glioma in three different classes, including chemoresistance, radioresistance, and glioma stem cell (GSC)-regulation. circRNAs act as competing endogenous RNA, sponging target microRNA and consequently affecting the expression of genes related to glioma tumorigenesis and resistance. By doing so, circRNAs can modulate the critical cellular pathways and processes regulating glioma resistance, including DNA repair pathways, GSC, epithelial-mesenchymal transition, apoptosis, and autophagy. Considering the poor survival and increased resistance to currently approved treatments for glioma, it is crucial to increase the knowledge of the resistance regulatory effects of circRNAs and their underlying molecular mechanisms. Herein, we conducted a comprehensive search and discussed the existing knowledge regarding the important role eof circRNAs in the emergence of resistance to therapeutic interventions in glioma. This knowledge may serve as a basis for enhancing the effectiveness of glioma therapeutic strategies.

Cancer, as a complicated disease, is considered to be one of the major leading causes of death globally. Although various cancer therapeutic strategies have been established, however, some issues confine the efficacies of the treatments. In recent decades researchers for finding efficient therapeutic solutions have extensively focused on the abilities of stem cells in cancer inhibition. Mesenchymal stem cells (MSCs) are multipotent stromal cells that can the most widely extracted from various sources such as the bone marrow (BM), placenta, umbilical cord (UC), menses blood, Wharton’s jelly (WJ), adipose tissue and dental pulp (DP). These cells are capable of differentiating into the osteoblasts, chondrocytes, and adipocytes. Due to the unique characteristics of MSCs such as paracrine effects, immunomodulation, tumor-tropism, and migration, they are considered promising candidates for cancer therapeutics. Currently, MSCs are an excellent living carrier for delivery of therapeutic genes and chemical agents to target tumor sites. Also, exosomes, the most important extracellular vesicle released from MSCs, act as a strong cell-free tool for cancer therapeutics. MSCs can prevent cancer progression by inhibiting several signaling pathways, such as wnt/β-catenin and PI3K/AKT/mTOR. However, there are several challenges associated with the use of MSCs and their exosomes in the field of therapy that need to be considered. This review explores the significance of MSCs in cell-based therapy, focusing on their homing properties and immunomodulatory characteristics. It also examines the potential of using MSCs as carriers for delivery of anticancer agents and their role in modulating the signal transduction pathways of cancer cells.

Hybrid nanocarriers have realized a growing interest in drug delivery research because of the potential of being able to treat, manage or cure diseases that previously had limited therapy or cure. Cancer is currently considered the second leading cause of death globally. This makes cancer therapy a major focus in terms of the need for efficacious and safe drug formulations that can be used to reduce the rate of morbidity and mortality globally. The major challenge encountered over the years with cancer chemotherapy is the non-selectivity of anticancer drugs, leading to severe adverse effects in patients. Multidrug resistance has also resulted in treatment failure in cancer chemotherapy over the years. Hybrid nanocarriers can be targeted to the site and offer co-delivery of two or more chemotherapeutics, thus leading to synergistic or additive results. This makes hybrid nanocarriers an extremely attractive type of drug delivery system for cancer therapy. Hybrid nanocarrier systems are also attracting attention as possible non-viral gene vectors that could have a higher level of transfection, and be efficacious, with the added advantage of being safer than viral vectors in clinical settings. An extensive review of various aspects of hybrid nanocarriers was discussed in this paper. It is envisaged that in the future, metastatic cancers, multi-drug resistant cancers, and low prognosis cancers like pancreatic cancers, will have a lasting solution via hybrid nanocarrier formulations with targeted co-delivery of therapeutics.

Candida albicans is an “opportunistic fungal agent” in cancer patients that can become colonized in both mucosal and deep tissues and cause severe infections. Most evidence has shown that C. albicans can enhance the progress of different cancers by several mechanisms such as generating virulence factors, participation in endogenous production of pro-inflammatory mediators, and stimulating a wide range of immune cells in the host. The main idea of this review is to describe a range of Candida-used mechanisms that are important in candidiasis-associated malignant processes and cancer development, particularly breast cancer. This review intends to provide a detailed discussion on different regulatory mechanisms of C. albicans that undoubtedly help to open new therapeutic horizons of cancer therapy in patients with fungal infection. The current therapeutic approach is not fully effective in immunocompromised and cancer patients, and further studies are required to find new products with effective antifungal properties and minimal side effects to increase the susceptibility of opportunistic fungal infections to conventional antifungal agents. So, in this situation, a special therapy should be considered to control the infection and simultaneously have the most therapeutic index on tumor patients.

Breast cancer is one of the most common cancers among women, and current treatments are inadequate due to unwarranted side effects and lack of specificity resulting in off target consequences. Artesunate is a synthetic anti-malarial drug that exerts inhibitory effects on cancer cell lines via apoptosis and has been used treating some cancers. This study investigated the anticancer effects of Fe3O4 magnetic nanoparticles conjugated with chitosan, polyethylene glycol, folic acid, and artesunate in vivo and in vitro.

Nanoparticles were synthesized by co-precipitation; morphology and size were determined by scanning electron microscopy (SEM), and the presence of the components was verified by nanoscale Fourier transform infrared spectroscopy (FTIR).  4T1 murine mammary tumor cells were treated with nanoparticles, and cell viability was determined by MTT assay. 4T1 cells were also subcutaneously injected into BALB/c mice, and magnetic resonance imaging was carried out two weeks later to determine tumor size among the groups.  Interferon gamma (IFN-γ) and IL-4 levels (in splenocytes culture supernatant) were measured by ELISA, and tumors, surrounding tissues, and mouse livers were histopathologically studied. 

The nanoparticle made in this article had good anticancer effects and caused apoptosis in cancer cells in breast cancer, and also strengthened the cellular immune system and further increased interferon gamma and increased the half-life of mice with cancer, while this nanoparticle It did not have the side effects of chemotherapy drugs.

Artesunate-containing nanoparticles decreased 4T1 cell viability and increased apoptosis to a greater extent than nanoparticles without the drug. In vivo, artesunate nanoparticles showed no toxicity and were more effective in decreasing tumor size than control. They were also associated with increased survival, increased IFN-γ, and decreased IL-4 levels in the spleen. The findings show the drug targets cancer  cells effectively with minimal side effects due to its herbal nature and targeted nano delivery.

Recently, the medical profession has seen an accelerated integration of devices equipped with artificial intelligence (AI) technology, thanks to significant advancements in this area. Over 60 medical devices integrated with AI have already received approval from the Food and Drug Administration (FDA) in the United States. The widespread use of AI technology in medicine is seen as an unavoidable trend soon. AI technology is now being used in the area of cancer, particularly in radiology, for clinical use of medical equipment. It is anticipated that AI technology will become a crucial core technology in this industry. Precision medicine, which involves selecting the most suitable treatment for each patient based on extensive medical data like genome information, has gained global popularity. AI technology is anticipated to play a crucial role in extracting valuable data from vast medical datasets and applying it to medical care. Cancer is the second most prevalent global illness that relies on oncogenic mutations and non-mutated genes for its survival. The significant variability of tumors may result in varying curative results when using the same medications or surgical procedures in people with the same tumor. This highlights the need for more precise treatment approaches for tumors and personalized therapies tailored to individual patients. We summarize current and noteworthy AI advances in cancer research in this report. We also discuss AI’s limitations, challenges, and potential effects on cancer therapy. We also explored AI in omics, pathology, and medical imaging.

Oncolytic viruses (OVs) are a promising cancer-fighting agent that has gained widespread attention due to recent advances in virology and molecular biology. These viruses selectively infect and multiply inside tumor cells, causing them to rupture and release newly synthesized viruses that stimulate the body's immune system to target the tumor cells. Clinical investigations have shown that OVs can effectively eliminate cancer cells that are resistant to traditional treatments, which is why over 100 clinical trials are currently exploring the possibility of combining them with other therapies for better efficacy. Although OVs have demonstrated enormous potential, their effectiveness in treating solid tumors is still limited. Therefore, researchers are continuously developing new viral families that can exclusively replicate in tumor cells. Currently, T-VEC is the only FDA-approved oncolytic virus, but with ongoing phase I-III clinical studies, more promising treatments are on the horizon. Furthermore, this review article provides a comprehensive overview of OVs, including their mechanism of action delivery routes, challenges in oncolytic virotherapy, current developments, the efficacy of OVs when combined with other cancer treatments, and prospects for future research.

Pro-inflammatory cytokines play critical roles in cancer pathobiology and have been considered potential targets for cancer management and therapy. Understanding the impact of cancer therapeutics such as 5-fluorouracil (5-FU) on their expression might shed light on development of novel combinational therapies. This study aimed to  encapsulate 5-FU into PLGA  and evaluate their effects on the expression of pro-inflammatory genes IL-9, IL-17-A, IL-23, and IFN-γ in the HT-29 cells.

PLGA-5-FU NPs were constructed and characterized by Dynamic Light Scattering (DLS) and Atomic Force Microscopy (AFM). The cytotoxicity was evaluated by MTT test and, the IC50 was identified. HT-29 cells were treated with different concentrations of the PLGA-5-FU NPs for 48 hours and, gene expression levels were analyzed by qRT-PCR.

DLS and AFM analysis revealed that the prepared PLGA-5-FU NPs were negatively charged spherical-shaped particles with a mean size of 215.9 ± 43.3 nm. PLGA-5-FU NPs impacted the viability of HT-29 cells in a dose- and time-dependent manner. The qRT-PCR results revealed a dose-dependent decrease in the expression of IL-9, IL-17A, IL-23 and IFN-γ genes, and their expressions were significantly different in both 10 and 20 µg/mL treated groups compared to the control. However, although the treatment of HT-29 cells with 20 µg/mL free 5-FU resulted in decreased expression of the studied genes, the differences were not statistically significant compared to the control group.

PLGA-5-FU NPs significantly suppressed expression of the IL-9, IL-17A, IL-23 and IFN-γ genes, and the encapsulation of 5-FU into PLGA improved considerably impact of the 5-FU on the HT-29 cells.

Immunotherapies that use the immune system to eliminate tumor cells have shown substantial therapeutic effectiveness in several types of human malignancies. Several investigations have emphasized the importance of neoantigens in the recognition of cancer cells by innate T lymphocytes. The identification of neoantigens, which are altered proteins that are selectively produced in tumor cells and not in healthy cells, has resulted in the development of enhanced cancer vaccines. Neoantigen targeting may stimulate anti-tumor T-cell reactions to eliminate tumors while sparing healthy cells from harm. Significant progress in DNA sequencing and computational biology has enabled the identification and development of potent neoantigens for application as therapeutic cancer vaccines. Therapeutic customized vaccines that target neoantigens have demonstrated encouraging outcomes in the field of cancer therapy. Therefore, this study aims to introduce neoantigens and their use in cancer immunotherapy.

Although nanoparticles (NPs) have many advantages as drug delivery systems, their poor stability in circulation, premature drug release, and nonspecific uptake in non-target organs have prompted biomimetic approaches to camouflage nano vehicles using natural cell membranes. Among them, which are extensively studied in erythrocytes, are the most abundant circulating blood cells. They are specially used for biomimetic coating on artificial NPs due to their excellent properties of good biocompatibility, biodegradability, non-immunogenicity, and long-term blood circulation. Erythrocyte-mimicking nanoparticles (EM-NPs) are prepared by combining nanoparticle cores with naturally derived erythrocyte (red blood cell or RBC) membranes. Compared with conventional nanosystems, EM-NPs hold the preferable characteristics of prolonged blood circulation time and immune evasion. In this review, the biomimetic platform of erythrocyte membrane-coated NPs is described in various aspects, with particular focus placed on the coating mechanism, preparation methods, characterization method, and recent advances in the biomedical applications of EM-NPs concerning cancer and targeted delivery.

Quantum dots (QDs) are semiconductor materials that range from 2 nm to 10 nm. These nanomaterials (NMs) are smaller and have more unique properties compared to conventional nanoparticles (NPs). One of the unique properties of QDs is their special optoelectronic properties, making it possible to apply these NMs in bioimaging. Different size and shape QDs, which are used in various fields such as bioimaging, biosensing, cancer therapy, and drug delivery, have so far been produced by chemical methods. However, chemical synthesis provides expensive routes and causes serious environmental and health issues. Therefore, various biological systems such as bacteria, fungi, yeasts, algae, and plants are considered as potent eco-friendly green nanofactories for the biosynthesis of QDs, which are both economic and environmentally safe. The review aims to provide a descriptive overview of the various microbial agents for the synthesis of QDs and their biomedical applications for the diagnosis and treatment of cancer and SARS-CoV-2.

Immunotherapy has changed the landscape of oncology over the last decade and has become a standard of care for various cancers. Researchers previously demonstrated that B16-F10 melanoma in C57Bl6 mice is resistant to immune checkpoint inhibitors. The goal of this study was to investigate how anti-PD1 antibodies functioned in combination with a new antimicrobial peptide (AMP) called moronecidin-like peptide (MLP). We studied the cytotoxic effect of AMP on the B10-F16 tumor cell line with the MTT experiment. The necrotic and apoptotic cells were determined by Presidium iodide (PI) /Annexin V staining and flow cytometry-based methods. Mice were inoculated subcutaneously with B10-F16 tumor cells in the mammary gland. Each group was sacrificed two weeks after the last injection to examine tumor-specific CD8+ T cell responses using flow cytometry.  Annexin V and PI staining assay revealed that MPL significantly induces apoptosis in B16F10 cells. It should be noted that MLP in combination with anti-PD-1 improved antigen-specific T-cell responses synergistically (P=0.01) when compared with respective monotherapy. Furthermore, when compared with the respective monotherapies, combination therapy significantly controlled tumor growth in B10-F16 tumor cells and increased survival rate. Treatments with anti-PD-1 inhibitors alone had only a minor effect on tumor size, whereas combination therapy resulted in significant tumor growth control and increased animal survival. MLP therapy combined with anti-PD-1 antibody improves anti-tumor immune response in addition to inducing tumor cell apoptosis. As a result, the evidence suggests that intratumoral injection of MPL can improve anti-PD-1 antibody antitumor response.

Progress in cancer stem cells has opened up a new window to develop better cancer treatment methods. Several pre-clinical and clinical trial studies use CSCs targeting via surface markers method and inhibition of stem cell pathway to eradicate cancer. Albite, some important question was unclear about CSCs origin and molecular mechanism of self-renewal, the structure of CSCs markers and so on, but the eradication of these cells eliminate cancer. In this review, we have argued about the CSC surface markers on different cancers, the mechanisms of action, and therapeutic procedures related to the cancer biomarkers. Then, we have discussed the challenges of these therapies.

Despite the progress made in the diagnosis and treatment of cancer, it has remained the second cause of death in industrial countries. Cancer is a complex multifaceted disease with unique genomic and proteomic hallmarks. Optogenetics is a biological approach, in which the light-sensitive protein modules in combination with effector proteins that trigger reversibly fundamental cell functions without producing a long-term effect. The technology was first used to address some key issues in neurology. Later on, it was also used for other diseases such as cancer. In the case of cancer, there exist several signaling pathways with key proteins that are involved in the initiation and/or progression of cancer. Such aberrantly expressed proteins and the related signaling pathways need to be carefully investigated in terms of cancer diagnosis and treatment, which can be managed with optogenetic tools. Notably, optogenetics systems offer some advantages compared to the traditional methods, including spatial-temporal control of protein or gene expression, cost-effective and fewer off-target side effects, and reversibility potential. Such noticeable features make this technology a unique drug-free approach for diagnosis and treatment of cancer. It can be used to control tumor cells, which is a favorable technique to investigate the heterogeneous and complex features of cancerous cells. Remarkably, optogenetics approaches can provide us with outstanding tool to extend our understanding of how cells perceive, respond, and behave in meeting with complex signals, particularly in terms of cancer evasion from the anticancer immune system functions.

Photothermal therapy (PTT) is a procedure that converts laser beam energy to heat socan disturb tumor cells. Carbon nanotubes (CNTs) have unique properties in absorption opticalenergy and could change optical power into heat in PTT procedures. Additionally, titaniumdioxide (TiO2) nanoparticles (NPs) have a unique feature in absorbing and scattering light.Therefore, these mentioned NPs could play a synergistic role in the PTT method.

CNTs and TiO2 NPs were injected into the melanoma tumor sites of cancerousmice. Then sites were excited using the laser beam (λ = 808 nm, P = 2 W, and I = 4 W/cm2).Injected NPs caused hyperthermia in solid tumors. Tumor size assay, statistical analysis, andhistopathological study of the treated cases were performed to assess the role of mentioned NPsin PTT of murine melanoma cancer.

The results showed that CNTs performed better than TiO2 NPs in destroying murinemelanoma cancer cells in animals.

The present study compared the photothermal activity of excited CNTs and TiO2NPs in cancer therapy at the near-infrared spectrum of light. Tumors were destroyed selectivelybecause of their weakened heat resistance versus normal tissue. PTT of malignant melanomathrough CNTs caused remarkable necrosis into the tumor tissues versus TiO2 NPs.

Vaccination is one of the important approaches in the prevention and control of diseases. Although the capacity to present antigens other than the disease-specific antigen in the traditional vaccine composition provides a potential benefit by increasing its protective efficacy, many components that are not needed for the related disease are also transferred. These components can reduce vaccine activity by lowering immunity against protective antigens. The reasons such as the low effectiveness of traditional vaccines and the high cost of production and time-consuming reasons show that it is necessary to develop a new vaccine method for our world, which is struggling with epidemics almost every year. Among nucleic acids, mRNA has many advantages, such as genomic integration, induction of anti-DNA autoantibodies, and immune tolerance induced by long-term antigen expression. mRNA vaccines have become a therapeutic target for reasons such as efficacy, safety, fast and non-expensive production. The fact that mRNA triggers both humoral and cellular immunity and goes only to the cytoplasm, not to the nucleus, makes it highly efficient. The mRNA must cross the lipid bilayer barrier and entry to the cytoplasm where it is translated into protein. There are two main ways of mRNA vaccine delivery for this: ex vivo loading of mRNA into dendritic cells and direct injection of mRNA with or without a carrier. Studies continue to understand which delivery system is therapeutically more efficient. Preclinical and clinical trials showed that mRNA vaccines trigger a long-lasting and safe immune response.

Breast cancer is a public health problem globally and is the most frequent cancer world wide. Currently, anti-inflammatory and anti-cancer drugs are of prime interest in treating some cancers especially breast cancer and have become an exciting challenge for researchers. The use of layered structures consisting of anions and cations called layered double hydroxides (LDHs) has attracted the attention of many researchers in the field of biomedical and pharmaceuticals. LDHs-nanostructures can be used as drug carriers, especially anti-inflammatory and anti-cancer drugs to treat cancers. Thus, the LDHs should have a number of physicochemical properties to act as a desirable drug carrier. Among the primary factors to increase the efficiency of LDHs are their surface characteristics and size, number and type of ions, rapid clearance from the body after drug release, and non-toxicity. All of these properties make LDHs nano-carriers for carrying anti-inflammatory and anti-cancer drugs to treat a variety of cancers. Therefore, we focus on reviewing the nature of LDH nano-carriers and evaluating the desirable properties for drug delivery, drug loading methods into LDH and anti-inflammatory drug delivery methods, their potential applications in biomedical and their toxicity and antimicrobial effects in breast cancer.

Cancer remains to be a major hurdle to global health. Exosomes as a versatile bio-derived platform, hold a bright prospect in nano-scaled delivery/targeting strategies. Shreds of evidence indicate that exosomes have a critical role in drug resistance in cancer cells through various mechanisms including shuttling of miRNAs, drug efflux transporters, and anti-apoptotic signaling. Exosomes’ cargo, particularly miRNAs, may exert both resistance and in a few cases sensitivity to the anticancer agents in targeted cells. Therefore, the source and components of the exosomes should be carefully considered before any application. Our aim in this editorial is to further highlight the role of exosomes in the development of resistance to therapy in cancer cells. As a new chapter for drug delivery, the challenges should be elucidated before exosomes emerge as novel nanoplatforms for cancer therapy.

Chemotherapy is a common treatment technique that uses chemical drugs to kill cancer cells. This technique affects normal healthy tissues being unspecific and has toxic adverse effects. Nowadays, nanotechnology applications in cancer chemotherapy have helped to solve the uncontrolled problems involving distribution of medicine particles and other side effects. Nanoparticles (NPs) can offer significant advantages over conventional drug delivery to have magnificent properties such as controlled mode of action, various methods of administration, and the ability to transport both organic/inorganic drug particles. Special ligands containing polymeric NPs preferentially hit the tumour site because of their chemical affinity to malignant tissues. This article, reviews the fabrication, characterization, and applications of NPs being used in chemotherapy. Furthermore, different forms of polymeric and especially polymeric chemotherapy were also explored and discussed to understand better the effects of NPs on cancer chemotherapy.

Ras proteins are considered as one of the most critical cancer initiators. Mutations of this protein family lead to the continuous activation of the proliferation pathways. Therefore, many efforts have been taken to design the anti-mutant Ras drug candidates. Regardless of the development of promising inhibitors of Ras G12C mutant in a specific cancer type, there is no approved inhibitor of Ras mutants in the clinic. One of the significant limitations is to inhibit particular mutants and not to affect the wild-type Ras variants. Here we present a review on the mechanism of action of the Ras proteins to get a better insight into the strategies utilized to inhibit Ras-mutated cancers. The direct Ras inhibition strategies are then highlighted to obtain a better perspective of possible promising approaches to target Ras proteins in cancer therapy